Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00092196 | Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED) | PHASE3 | COMPLETED | 820 | — | — | Dec 1, 2002 | Dec 1, 2004 | May 5, 2017 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0869, aprepitant / Duration of Treatment: 3 days | DRUG | - |
Inclusion Criteria: * Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy. * Patient must have completed participation in the main study for this protocol. Exclusion Criteria: * Patient has a central nervous system malignancy. * Pati...